Sign In
Buy AGNPF
$0.248
-0.0513 (-17.12%)
At Close: Jul 31, 2026
Algernon Pharmaceuticals announces Phase 2b study of Ifenprodil for chronic cough
08:39am, Monday, 09'th Jan 2023
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has announced that it is planning a 180-patient, 90-day, Phase 2b clinical study of NP-120 (Ifenprodil) for chronic cough set to begin in the third
Algernon Pharmaceuticals forms private subsidiary to advance psychedelic DMT stroke program
07:59am, Tuesday, 03'rd Jan 2023
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said it has set up Algernon NeuroScience (AGN Neuro), a new wholly-owned private subsidiary of AGN Pharma, to advance its psychedelic DMT (N,N-Dime
Algernon Pharma inks equity distribution agreement to raise aggregate gross proceeds of up to $5.0M
07:36am, Tuesday, 27'th Dec 2022
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said it has entered into an equity distribution agreement dated December 23, 2022, with Research Capital Corp for the at-the-market (ATM) offering
Algernon Pharmaceuticals says Ifenprodil granted Orphan Drug Designation by US FDA for treatment of IPF
07:57am, Monday, 05'th Dec 2022
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Ifenprodil as a treatment for idiopathic pulmonary fibr
Algernon Pharmaceuticals poised for enrollment into Phase 1 DMT stroke study in Netherlands; aims to dose first subject in December
09:14am, Wednesday, 16'th Nov 2022
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) told investors it had started screening people to take part in its Phase 1 clinical study of an intravenous formulation of AP-188, or DMT to treat
Algernon Pharmaceuticals enters clinical trial agreement with Yale University for DMT phase 2 depression study
08:13am, Monday, 24'th Oct 2022
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said it has entered into an investigator-initiated clinical trial agreement (CTA) with Yale University for the investigation of multiple intravenou
Algernon Pharmaceuticals says DMT research expert Dr Rick Strassman to join CEO for keynote address at Wonderland conference
08:04am, Friday, 14'th Oct 2022
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has announced that Dr Rick Strassman, author of the book 'DMT: The Spirit Molecule' and an Algernon consultant, will join the company's CEO Chris
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said it has filed a request for Orphan Designation with the US Food and Drug Administration (FDA) for the use of Ifenprodil as a treatment for idio
Algernon Pharmaceuticals granted approval for Phase 1 human DMT study for treatment of stroke in the Netherlands
09:10am, Monday, 12'th Sep 2022
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said it has received approval from the independent Medical Research Ethics Committee of the Netherlands, the Stichting Beoordeling Ethiek Biomedis
Algernon Pharmaceuticals announces its headline sponsorship of Wonderland, a key gathering for the psychedelic medicine industry
07:55am, Thursday, 08'th Sep 2022
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has announced that it will be the headline sponsor for Wonderland, a key gathering in the psychedelic medicine industry, to be held at the Mana Wyn
Algernon Pharmaceuticals says global expert on IPF describes results from Phase 2a study on Ifenprodil as 'excellent'
08:11am, Thursday, 01'st Sep 2022
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) told investors it has now received the full data set from its Phase 2a study assessing Ifenprodil to treat idiopathic pulmonary fibrosis (IPF) and
Algernon Pharmaceuticals closes previously announced non-brokered private placement for gross proceeds of $1,402,125
07:57am, Tuesday, 23'rd Aug 2022
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said it has closed its previously announced non-brokered private placement in the amount of 373,900 units at a price of $3.75 each for gross procee
Algernon Pharmaceuticals announces non-brokered private placement
08:40am, Thursday, 18'th Aug 2022
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has announced a non-brokered private placement for gross proceeds of $1,402,125 to fund research and development programs, general and administrati
Algernon Pharmaceuticals says it has been invited to present IPF and chronic cough study data at American Cough Conference next year
08:21am, Wednesday, 03'rd Aug 2022
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said it has been invited to present the results from its phase 2a study of NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic
Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference
07:07am, Wednesday, 03'rd Aug 2022
VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadia
